{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:47Z","timestamp":1793730947086,"version":"4.6.1"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1001\/jamacardio.2019.1041","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T11:42:40Z","timestamp":1556106160000},"page":"575","source":"Crossref","is-referenced-by-count":216,"title":["Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes"],"prefix":"10.1001","volume":"4","author":[{"given":"Claudia","family":"Lamina","sequence":"first","affiliation":[{"name":"Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Lp(a)-GWAS-Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hbr190007r1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics.","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"issue":"10","key":"hbr190007r2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease: a study in six populations.","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler Thromb"},{"issue":"19","key":"hbr190007r3","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"hbr190007r4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"26","key":"hbr190007r5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"17","key":"hbr190007r6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA variants are associated with residual cardiovascular risk in patients receiving statins.","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"issue":"10057","key":"hbr190007r7","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"hbr190007r8","doi-asserted-by":"publisher","first-page":"e001696","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study.","volume":"11","author":"Parish","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"7","key":"hbr190007r9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis.","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hbr190007r10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms.","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"issue":"11","key":"hbr190007r11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.v35.11","article-title":"Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods.","volume":"35","author":"Burgess","year":"2016","journal-title":"Stat Med"},{"issue":"6","key":"hbr190007r12","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","article-title":"MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data.","volume":"46","author":"Yavorska","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"9753","key":"hbr190007r13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"hbr190007r14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome.","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int"},{"issue":"32","key":"hbr190007r15","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"hbr190007r16","article-title":"Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER trial.","author":"O\u2019Donoghue","year":"2018","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/6\/575\/17664456\/jamacardiology_lamina_2019_br_190007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T11:01:18Z","timestamp":1560942078000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.1041"}},"subtitle":["A Mendelian Randomization Analysis"],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.1041","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}